• RSS
    • Twitter
    • Facebook
    • Email
    • LinkedIn
    Partner Therapeutics
    • About PTx
      • Leadership
      • Compliance
      • Business Development
      • Careers
      • News
    • Products
      • BIZENGRI® (zenocutuzumab-zbco)
      • LEUKINE® (sargramostim)
    • Research
      • Our Approach
      • Sargramostim
        • Clinical Trials
        • Publications
      • Zenocutuzumab
        • About
        • Clinical Trials
        • Publications
    • Medical Info
      • Medical Inquiries
    • Contact Us
      • Contact Information
      • Lexington, MA
      • Lynnwood, WA

    jQuery3 – Full width image

    Continue Reading →
    10
    JAN
    2014
    0

    Search

    Archives

    • February 2025 (1)
    • January 2025 (1)
    • December 2024 (2)
    • April 2024 (2)
    • January 2024 (1)
    • December 2023 (1)
    • November 2023 (1)
    • December 2022 (1)
    • March 2022 (1)
    • February 2022 (1)
    • September 2021 (1)
    • August 2021 (1)
    • June 2021 (1)
    • May 2021 (1)
    • April 2021 (1)
    • March 2021 (2)
    • February 2021 (2)
    • September 2020 (2)
    • August 2020 (2)
    • June 2020 (1)
    • May 2020 (1)
    • March 2020 (1)
    • November 2019 (1)
    • September 2019 (1)
    • November 2018 (1)
    • June 2018 (1)
    • May 2018 (1)
    • March 2018 (1)
    • February 2018 (3)
    • January 2018 (1)
     
     

    Latest News

    •  

      New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer

      ...

    •  

      BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis

      ...

    •  

      Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

      ...


    Join Our Team

    Partner Therapeutics (PTx) is a commercial biotech committed to improving the lives of patients with cancer and other serious diseases. We're looking for passionate professionals to join us with expertise that spans the biopharma value chain.

     

    View Current Openings
      © 2024 Partner Therapeutics, Inc.
    • Home
    • News
    • Privacy Policy
    • Terms of Use